Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat. Due to the asymptomatic nature of the disease and lack of curative treatment modalities, the 5-y survival rate of PDAC patients is one of the lowest of any cancer type. The recurrent genetic alterations in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Proc Natl Acad Sci U S A
Auteurs principaux: Wei, Xiaolong, Yang, Jiekun, Adair, Sara J., Ozturk, Harun, Kuscu, Cem, Lee, Kyung Yong, Kane, William J., O’Hara, Patrick E., Liu, Denis, Demirlenk, Yusuf Mert, Habieb, Alaa Hamdi, Yilmaz, Ebru, Dutta, Anindya, Bauer, Todd W., Adli, Mazhar
Format: Artigo
Langue:Inglês
Publié: National Academy of Sciences 2020
Sujets:
Biological Sciences
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7668168/
https://ncbi.nlm.nih.gov/pubmed/33097661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.2009899117
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires